To JUPITER and beyond: statins, inflammation, and primary prevention.
作者信息
Rao Ajay D, Milbrandt Eric B
机构信息
Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
出版信息
Crit Care. 2010;14(3):310. doi: 10.1186/cc9006. Epub 2010 May 13.
Abstract
摘要
相似文献
1
To JUPITER and beyond: statins, inflammation, and primary prevention.
Crit Care. 2010;14(3):310. doi: 10.1186/cc9006. Epub 2010 May 13.
2
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.
3
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.
World J Cardiol. 2011 Jul 26;3(7):207-14. doi: 10.4330/wjc.v3.i7.207.
4
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22.
5
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1.
6
Impact of the JUPITER trial on statin prescribing for primary prevention.
Pharmacotherapy. 2014 Jan;34(1):9-18. doi: 10.1002/phar.1340. Epub 2013 Aug 12.
7
Extreme all-cause mortality in JUPITER requires reexamination of vital records.
Cardiology. 2011;120(2):84-8. doi: 10.1159/000330507. Epub 2011 Dec 2.
8
[Primary prevention trials performed with statins prior to the JUPITER trial].
Turk Kardiyol Dern Ars. 2009 Apr;37 Suppl 4:14-7.
9
C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?
Ochsner J. 2009 Winter;9(4):204-10.
10
Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
Int J Occup Environ Health. 2012 Jan-Mar;18(1):70-8. doi: 10.1179/1077352512Z.0000000008.
引用本文的文献
1
Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease.
ARYA Atheroscler. 2016 Sep;12(5):231-237.
2
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
PLoS One. 2012;7(7):e40673. doi: 10.1371/journal.pone.0040673. Epub 2012 Jul 16.
3
Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index.
Korean Circ J. 2012 Mar;42(3):164-72. doi: 10.4070/kcj.2012.42.3.164. Epub 2012 Mar 26.
4
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.
本文引用的文献
1
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial).
Crit Care. 2012 Dec 11;16(6):R231. doi: 10.1186/cc11895.
2
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial.
Trials. 2012 Sep 17;13:170. doi: 10.1186/1745-6215-13-170.
3
Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
Curr Med Res Opin. 2010 Oct;26(10):2485-97. doi: 10.1185/03007995.2010.516994.
4
Statins for sepsis: a critical and updated review.
Clin Microbiol Infect. 2009 Apr;15(4):325-34. doi: 10.1111/j.1469-0691.2009.02750.x.
5
A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.
Intensive Care Med. 2009 Apr;35(4):717-21. doi: 10.1007/s00134-008-1358-3. Epub 2008 Nov 26.
6
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
7
Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1242-7. doi: 10.1164/rccm.200712-1777OC. Epub 2008 Mar 27.
8
Statin treatment after onset of sepsis in a murine model improves survival.
Circulation. 2005 Jul 5;112(1):117-24. doi: 10.1161/CIRCULATIONAHA.104.502195.
9
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.
Circulation. 2004 Jun 1;109(21):2560-5. doi: 10.1161/01.CIR.0000129774.09737.5B. Epub 2004 May 3.
10
Statins, inflammation, and sepsis: hypothesis.
Chest. 2003 Aug;124(2):740-3. doi: 10.1378/chest.124.2.740.
Zotero 插件